---
title: "2026ASCO GI:食管鳞癌新辅助放化免 vs 新辅助放化疗"
date: 2026-01-22T05:19:09Z
draft: ["false"]
tags: [
  "fetched",
  "食管癌前沿"
]
categories: ["Acdemic"]
---
2026ASCO GI:食管鳞癌新辅助放化免 vs 新辅助放化疗 by 食管癌前沿
------
<div><section><img data-aistatus="1" data-imgfileid="508706710" data-ratio="0.16346153846153846" data-s="300,640" data-type="png" data-w="312" type="block" data-src="https://mmbiz.qpic.cn/mmbiz_png/vo5K16kud46nsyEJ2kstQOSiaAKXLuHa8rT5mwnrIibVACBk9Fvdatelqtf3wNxpot5p0TXicqYaDKjNuTOXAQ1Rg/640?wx_fmt=png&amp;from=appmsg" src="https://mmbiz.qpic.cn/mmbiz_png/vo5K16kud46nsyEJ2kstQOSiaAKXLuHa8rT5mwnrIibVACBk9Fvdatelqtf3wNxpot5p0TXicqYaDKjNuTOXAQ1Rg/640?wx_fmt=png&amp;from=appmsg"></section><section><img data-aistatus="1" data-imgfileid="508706711" data-ratio="1.4772727272727273" data-s="300,640" data-type="png" data-w="396" type="block" data-src="https://mmbiz.qpic.cn/mmbiz_png/vo5K16kud46nsyEJ2kstQOSiaAKXLuHa8FMJ45kX2HCqlKCXpClu3FnkqfS5z1pfjQMXibxANChuicb9B1kMzDwYw/640?wx_fmt=png&amp;from=appmsg" src="https://mmbiz.qpic.cn/mmbiz_png/vo5K16kud46nsyEJ2kstQOSiaAKXLuHa8FMJ45kX2HCqlKCXpClu3FnkqfS5z1pfjQMXibxANChuicb9B1kMzDwYw/640?wx_fmt=png&amp;from=appmsg"></section><section><b msttexthash="13368446" msthash="1138" data-pm-slice="0 0 []"><span leaf="">背景：</span></b><font mstmutation="1" msttexthash="1978665416" msthash="1139"><span leaf="">虽然新辅助同步放化疗（cCRT）仍是可切除食管鳞状细胞癌（ESCC）的新辅助治疗标准，但病理完全反应（pCR）率仍不理想（20</span><span mstmutation="1" istranslated="1"><span leaf="">–30%）。免疫疗法已在晚期ESCC中证明有效，其与cCRT在新辅助环境中的潜在协同效应值得深入研究。</span></span></font><p><span leaf=""><br></span></p><b msttexthash="12908077" msthash="1140"><span leaf="">方法：</span></b><font mstmutation="1" msttexthash="13726998935" msthash="1141"><span leaf="">在这项多中心随机二期试验中，我们计划招募100名可切除ESCC（T1-3N+M0/T3NanyM0）患者。参与者被1：1随机分配接受抗PD-L1抗体Benmelstobart（1200mg，D1和22）+ cCRT（紫杉醇50 mg/m²</span><span mstmutation="1" istranslated="1"><span leaf="">+卡铂AUC2，每周一次，放疗41.4 Gy/23分组）或单独cCRT，按cT分期（T1-2 vs T3）分层。手术在治疗后6-8周进行。主要终点为pCR率。次要终点包括主要病理反应（MPR）、客观反应率（ORR）、疾病控制率（DCR）、R0切除率、1年无病生存期（DFS）、1年总体生存期（OS）、新辅助治疗完成率及安全性。如果</span></span><span mstmutation="1" istranslated="1"><span leaf="">BEN +cCRT组前30名患者中有≥18人达到pCR</span></span><span leaf="">，预先计划进行放射降级（36 Gy）。</span></font><p><span leaf=""><br></span></p><b msttexthash="13353795" msthash="1142"><span leaf="">结果：</span></b><font mstmutation="1" msttexthash="12866836450" msthash="1143"><span leaf="">从2024年10月24日至2025年8月31日，82名患者被随机分配到BEN + cCRT组（n=42）或cCRT组（n=40）。分别有30名和36名患者完成了新辅助疗法，7名和4名仍在治疗中。此外，BEN + cCRT组中，4名患者在随机分组后退出，1名患者未完成新辅助治疗而退出。BEN +cCRT组有18例，cCRT组有24例接受食管切除术，术后病理可查。</span></font></section><section><font mstmutation="1" msttexthash="12866836450" msthash="1143"><span leaf="">其中两组均为100%切除R0。</span></font></section><section><font mstmutation="1" msttexthash="12866836450" msthash="1143"><span leaf="">pCR率为50%（9/18）对比42%（10/24），MPR率分别为78%（14/18）和63%（15/24）。</span></font></section><section><font mstmutation="1" msttexthash="12866836450" msthash="1143"><span leaf="">在</span><span mstmutation="1" istranslated="1"><span leaf="">40%和35%的患者中观察到≥3级治疗相关不良事件（TRAEs），其中血液毒性最为常见。未</span></span><span mstmutation="1" istranslated="1"><span leaf="">观察到≥3级辐射食管炎或5级TEAEs。</span></span></font><p><span leaf=""><br></span></p><b msttexthash="14315379" msthash="1144"><span leaf="">结论：</span></b><font mstmutation="1" msttexthash="1134582384" msthash="1145"><span leaf="">新辅助免疫</span><font mstmutation="1" msttexthash="13726998935" msthash="1141"><span leaf="" data-pm-slice='1 1 ["para",null,"node",{"tagName":"font","attributes":{"_mstmutation":"1","_msttexthash":"13726998935","_msthash":"1141","style":"box-sizing: border-box; color: rgb(33, 37, 41); font-family: Inter, Roboto, \"Open Sans\", Helvetica, Arial, sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0.5px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'>Benmelstobart</span></font><span leaf="">联合cCRT显示出令人鼓舞的初步疗效，包括高pCR和MPR率，以及可切除ESCC的可控安全性。持续的入组和随访将进一步阐明该方案的临床益处。</span></font></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/OS3DkhmxHqwPDDyRrRW_1A",target="_blank" rel="noopener noreferrer">原文链接</a>
